New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million ...

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created

Related Keywords

Denmark ,United States ,California ,Germany ,Russia ,Ukraine ,Redwood City ,Copenhagen ,Køavn ,Conrad Wang ,Danna Chen ,Emmett Cunningham ,Daniel Estes ,Ascendis Pharma ,Yvonne Yamanaka ,Jan Mikkelsen ,Oliver Boris Stauch ,Frazier Life Sciences Of Eyconis Inc ,Exchange Commission ,Frazier Life Sciences ,Senior Partner ,Healthquest Capital ,Executive Chairman ,Chief Operating Officer ,Eyconi Executive ,Chief Executive ,Ascendi Annual Report ,Region ,